Trovagene Investor Relations http://trovagene.investorroom.com/ Trovagene Investor Relations Trovagene Announces Leadership Change http://trovagene.investorroom.com/2018-06-22-Trovagene-Announces-Leadership-Change William Welch has resigned as CEO and Director Fri, 22 Jun 2018 14:19:00 -0700 http://trovagene.investorroom.com/2018-06-22-Trovagene-Announces-Leadership-Change Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC http://trovagene.investorroom.com/2018-06-21-Trovagene-Announces-the-Start-of-Recruitment-and-Enrollment-for-Phase-2-Clinical-Trial-of-PCM-075-in-Combination-with-Zytiga-R-in-Patients-with-mCRPC Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and recruiting patients for Phase 2 open-label trial of PCM-075 and abiraterone acetate (Zytiga®) in metastatic Castration-Resistant Prostate Cancer (mCRPC) Thu, 21 Jun 2018 05:00:00 -0700 http://trovagene.investorroom.com/2018-06-21-Trovagene-Announces-the-Start-of-Recruitment-and-Enrollment-for-Phase-2-Clinical-Trial-of-PCM-075-in-Combination-with-Zytiga-R-in-Patients-with-mCRPC Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial http://trovagene.investorroom.com/2018-06-15-Trovagene-Announces-Completion-of-First-Dosing-Cohort-of-Patients-Treated-with-PCM-075-in-Combination-with-Decitabine-in-Ongoing-Phase-1b-2-AML-Trial Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with decitabine in dose-escalation phase of trial Fri, 15 Jun 2018 05:00:00 -0700 http://trovagene.investorroom.com/2018-06-15-Trovagene-Announces-Completion-of-First-Dosing-Cohort-of-Patients-Treated-with-PCM-075-in-Combination-with-Decitabine-in-Ongoing-Phase-1b-2-AML-Trial Trovagene, Inc. Announces Closing of $18 Million Public Offering http://trovagene.investorroom.com/2018-06-12-Trovagene-Inc-Announces-Closing-of-18-Million-Public-Offering Tue, 12 Jun 2018 10:05:00 -0700 http://trovagene.investorroom.com/2018-06-12-Trovagene-Inc-Announces-Closing-of-18-Million-Public-Offering Trovagene, Inc. Announces Pricing of $18 Million Public Offering http://trovagene.investorroom.com/2018-06-07-Trovagene-Inc-Announces-Pricing-of-18-Million-Public-Offering Thu, 07 Jun 2018 20:21:00 -0700 http://trovagene.investorroom.com/2018-06-07-Trovagene-Inc-Announces-Pricing-of-18-Million-Public-Offering